(Q79443178)

English

p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study

scientific article published on 25 December 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Kazuharu Kai

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Reiki Nishimura

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Nobuyuki Arima

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Haruhiko Miyayama

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Hirotaka Iwase

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

25 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

426-433

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

https://scigraph.springernature.com/pub.10.1007/s10147-006-0601-6

0 references

Analysis of the factors influencing the quality of life of patients with advanced or recurrent breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Grou

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response to systemic therapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular markers for predicting response to tamoxifen in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/17180510

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-006-0601-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17180510%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79443178&oldid=1398376453"